



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
David Yang et al.

Serial No.: 10/672,763

Filed: September 26, 2003

For: ETHYLENEDICysteine (EC)-DRUG  
CONJUGATES, COMPOSITIONS AND  
METHODS FOR TISSUE SPECIFIC  
DISEASE IMAGING

Group Art Unit: 1616

Examiner: Unknown

Atty. Dkt. No.: UTSC:664USC1

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being  
deposited with the U.S. Postal Service with  
sufficient postage as First Class Mail in an  
envelope addressed to: MS Amendment,  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, on the date below:

February 4, 2005  
Date

Monica A. De La Paz

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:664USC1.

This application is a continuation application of Serial No. 09/599,152, filed June 21, 2000 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. 09/599,152 are enclosed for the convenience of the Examiner.

This application is related by subject matter and inventorship to US Application Nos. 10/672,142 filed September 26, 2003, 10/703,405 filed November 7, 2003, and 10/732,919 filed December 10, 2003.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Monica A. De La Paz  
Reg. No. 54,662  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: February 4, 2005



## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

MDELAPAZ@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-5639

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

February 4, 2005

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:

February 4, 2005

Date

Monica A. De La Paz

### MS AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U. S. Patent Application No. 10/672,763 "ETHYLENEDICYSSTEINE (EC)-DRUG  
CONJUGATES, COMPOSITIONS AND METHODS FOR TISSUE SPECIFIC DISEASE IMAGING" –  
David Yang, et al.

Our Ref. No. UTSC:664USC1  
UT Ref No.: MDA99-040

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449 and references A44-A55, B11, and C340-C366.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:664USC1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Monica A. De La Paz  
Reg. No. 54,662

MAD/kvp  
Encl.: as noted

25497755.1

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:664USC1

Serial No.

10/672,763

List of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 26, 2003

Group:

1616

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A44	4,279,992	7/21/81	Boguslaski <i>et al.</i>	435	7	10/23/79
	A45	4,789,542	12/06/88	Goodman and Knapp, Jr.	424	1.1	4/29/86
	A46	4,824,659	4/25/89	Hawthorne	424	1.1	6/07/85
	A47	5,013,556	5/07/91	Woodle <i>et al.</i>	424	450	10/20/89
	A48	5,356,793	10/18/94	Koezuka <i>et al.</i>	435	32	2/01/91
	A49	5,643,883	6/01/97	Marchase and Darbha	514	23	1/19/95
	A50	5,688,487	11/18/97	Linder <i>et al.</i>	424	1.65	6/06/95
	A51	5,834,266	11/10/98	Crabtree <i>et al.</i>	435	172.3	8/18/94
	A52	5,877,289	3/02/99	Thorpe and Edgington	530	387.1	6/07/95
	A53	5,891,468	4/06/99	Martin and Zalipsky	424	450	10/10/97
	A54	6,033,884	3/07/00	Woo <i>et al.</i>	435	172.3	12/14/93
	A55	6,054,436	4/25/00	Crabtree <i>et al.</i>	514	31	5/29/98

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B11	WO 98/08859	3/05/98	WIPO			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C340	Boersma <i>et al.</i> , "Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin," <i>Cytometry</i> , 24:123-130, 1996.
	C341	Cafaggi <i>et al.</i> , "Synthesis and antitumor activity of a new cis-diammineplatinum (III) complex containing procaine hydrochloride," <i>Anticancer Research</i> , 12:2285-2292, 1992.

25497736.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1616
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C342	Cammisuli <i>et al.</i> , "SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo," <i>Int J Cancer</i> , 65:351-359, 1996.
	C343	Chakrabarti <i>et al.</i> , "Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties," <i>Biochemical Pharmacology</i> , 56:1471-1479, 1998.
	C344	Connors, "Anticancer drug development: the way forward," <i>The Oncologist</i> , 1:180-181, 1996.
	C345	Guo and Gallo, "Selective protection of 2', 2'-difluorodeoxycytidine (Gemcitabine)," <i>J Org Chem</i> , 64:8319-8322, 1999.
	C346	Hirsch <i>et al.</i> , "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection," <i>Experimental Cell Research</i> , 241:426-434, 1998.
	C347	Hjarnaa <i>et al.</i> , "CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo," <i>Cancer Res.</i> , 59:5751-5757, 1999.
	C348	Inoue <i>et al.</i> , "Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel," <i>Annals of Nuclear Medicine</i> , 13(3):169-174, 1999.
	C349	Jiang <i>et al.</i> , "Antitumor activity of didemnin B in the human tumor stem cell assay," <i>Cancer Chemother Pharmacol</i> , 11:1-4, 1983.
	C350	Jiang <i>et al.</i> , "3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells," <i>Cancer Res.</i> , 58:5389-5395, 1998.
	C351	LeClerc and Cedergren, "Modeling RNA-ligand interactions: the rev-binding element RNA-aminoglycoside complex," <i>J Med Chem</i> , 41:175-182, 1998.
	C352	Lundberg <i>et al.</i> , "Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions," <i>J Pharm Pharmacol</i> , 51:1099-1105, 1999.
	C353	McGahon <i>et al.</i> , "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system," <i>British Journal of Haematology</i> , 101:539-547, 1998.
	C354	Meyer <i>et al.</i> , "Tryptophan hydrolase antibodies used in the diagnosis of carcinoid," <i>Hepato-Gastroenterology</i> , 45:1522-1526, 1998.

25497736.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:664USC1	Serial No. 10/672,763
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant David Yang <i>et al.</i>	
	Filing Date: September 26, 2003	Group: 1616
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C355	Murray <i>et al.</i> , "Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer," <i>Journal of Pathology</i> , 185:256-261, 1998.
	C356	Palyi <i>et al.</i> , "Effects of methylacetylenic putrescine, and ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines," <i>Anti-Cancer Drugs</i> , 10:103-111, 1999.
	C357	Pavicevic <i>et al.</i> , "Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer," <i>Coll Antropol</i> , 22(2):629-635, 1998.
	C358	Pavlik <i>et al.</i> , "Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity," <i>Cancer Chemother Pharmacol</i> , 11:8-15, 1983.
	C359	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int J Radiation Oncology Biol Phys</i> , 17:985-991, 1989.
	C360	Rasey <i>et al.</i> , "Characteristics of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiation Research</i> , 122:301-308, 1990.
	C361	Reutelingsperger and van Heerde, "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis," <i>Cell Mol Life Sci</i> , 53:527-532, 1997.
	C362	Thompson, "Apoptosis in the pathogenesis and treatment of disease," <i>Science</i> , 267:1456-1462, 1995.
	C363	Tolomeo <i>et al.</i> , "The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis," <i>Cell Death and Differentiation</i> , 5:735-742, 1998.
	C364	Van den Eijnde <i>et al.</i> , "In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure," <i>Cytometry</i> , 29:313-320, 1997.
	C365	Wright <i>et al.</i> , "Aminoglycoside antibiotics: structures, functions, and resistance," In: <i>Resolving the Antibiotic Paradox</i> , Rosen and Mobashery eds, Kluwer Academic/Plenum Pub NY, 1998.
	C366	Yoshinari <i>et al.</i> , "Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I," <i>Cancer Res.</i> , 59:4271-4275, 1999.

25497736.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.